IL2RA and non-Hodgkin lymphoma: A report based on the Transplant Cancer Match Study, including 111,857 adult patients after kidney transplantation, revealed that specific biologic agents which significantly increased the incidence of NHL were alemtuzumab (aIRR 1.79) and muorab-CD3 (aIRR 1.37), while the use of polyclonal depletive agents (aIRR 0.96) or anti-IL2R monoclonals (aIRR 0.82) was not associated with a higher risk of NHL.